Lazard Asset Management Portfolio holdings
AUM
$72.7B
1-Year Return
14.89%
This Quarter Return
+8.56%
1 Year Return
+14.89%
3 Year Return
+61.14%
5 Year Return
+112.7%
10 Year Return
+262.42%
AUM
$82.3B
AUM Growth
+$3.23B
(+4.1%)
Cap. Flow
-$8.69B
Cap. Flow
% of AUM
-10.56%
Top 10 Holdings %
Top 10 Hldgs %
24.03%
Holding
2,529
New
201
Increased
563
Reduced
953
Closed
424
Top Buys
| 1 |
Apple
AAPL
|
+$927M |
| 2 |
Exelon
EXC
|
+$625M |
| 3 |
Broadcom
AVGO
|
+$519M |
| 4 |
CRH
CRH
|
+$437M |
| 5 |
Marvell Technology
MRVL
|
+$283M |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$839M |
| 2 |
Norfolk Southern
NSC
|
+$575M |
| 3 |
PPL Corp
PPL
|
+$355M |
| 4 |
Union Pacific
UNP
|
+$328M |
| 5 |
Cisco
CSCO
|
+$284M |
Sector Composition
| 1 | Technology | 23.46% |
| 2 | Financials | 14.23% |
| 3 | Healthcare | 13.09% |
| 4 | Industrials | 10.07% |
| 5 | Consumer Discretionary | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Caribou Biosciences
CRBU
$166M
| $20K | ﹤0.01% |
4,221
-17,068
| -80% | -$80.9K |
|
1677
CGI
GIB
$20.7B
| $20K | ﹤0.01% |
186
| – | – |
|
1678
Legend Biotech
LEGN
$6.18B
| $20K | ﹤0.01% |
380
-210
| -36% | -$11.1K |
|
1679
Plumas Bancorp
PLBC
$313M
| $20K | ﹤0.01% |
554
-1
| -0.2% | -$36 |
|
1680
Sun Life Financial
SLF
$33B
| $20K | ﹤0.01% |
+380
| New | +$20K |
|
|
BLUE
1681
DELISTED
bluebird bio
BLUE
| $19K | ﹤0.01% |
759
+416
| +121% | +$10.4K |
|
1682
CoreCivic
CXW
$2.18B
| $19K | ﹤0.01% |
1,275
-3,768
| -75% | -$56.2K |
|
1683
TScan Therapeutics
TCRX
$104M
| $19K | ﹤0.01% |
2,551
-1,432
| -36% | -$10.7K |
|
1684
Tecnoglass
TGLS
$3.36B
| $19K | ﹤0.01% |
384
-6,824
| -95% | -$338K |
|
|
VBNK
1685
VersaBank
VBNK
$380M
| $19K | ﹤0.01% |
+1,850
| New | +$19K |
|
1686
Integra LifeSciences
IART
$1.2B
| $18K | ﹤0.01% |
+534
| New | +$18K |
|
1687
Tango Therapeutics
TNGX
$708M
| $18K | ﹤0.01% |
2,349
-1,307
| -36% | -$10K |
|
1688
TransUnion
TRU
$17.5B
| $18K | ﹤0.01% |
235
-15
| -6% | -$1.15K |
|
1689
Capricor Therapeutics
CAPR
$289M
| $17K | ﹤0.01% |
+2,693
| New | +$17K |
|
1690
Lyell Immunopharma
LYEL
$251M
| $17K | ﹤0.01% |
396
-224
| -36% | -$9.62K |
|
1691
Tenaya Therapeutics
TNYA
$212M
| $17K | ﹤0.01% |
3,354
-1,853
| -36% | -$9.39K |
|
1692
Allogene Therapeutics
ALLO
$246M
| $16K | ﹤0.01% |
3,861
-2,137
| -36% | -$8.86K |
|
1693
DXP Enterprises
DXPE
$1.79B
| $16K | ﹤0.01% |
312
-1,634
| -84% | -$83.8K |
|
1694
Taysha Gene Therapies
TSHA
$887M
| $16K | ﹤0.01% |
5,804
-3,001
| -34% | -$8.27K |
|
|
CTLT
1695
DELISTED
CATALENT, INC.
CTLT
| $16K | ﹤0.01% |
291
-125,362
| -100% | -$6.89M |
|
1696
Sangamo Therapeutics
SGMO
$160M
| $15K | ﹤0.01% |
23,437
-13,653
| -37% | -$8.74K |
|
1697
Biohaven
BHVN
$1.48B
| $14K | ﹤0.01% |
272
-11
| -4% | -$566 |
|
1698
Core Molding Technologies
CMT
$180M
| $14K | ﹤0.01% |
742
-158
| -18% | -$2.98K |
|
1699
Sabre
SABR
$679M
| $14K | ﹤0.01% |
5,810
+5,274
| +984% | +$12.7K |
|
1700
Sabesp
SBS
$15.8B
| $14K | ﹤0.01% |
884
-113
| -11% | -$1.79K |
|